Corilagin, a gallotannin, is one of the major active components of many ethnopharmacological plants. It was isolated from (Jacq.) Willd. (dividivi) by Schmidt in 1951 for the first time. In the past few decades, corilagin was reported to exhibit anti-tumor, anti-inflammatory and hepatoprotective activities, . However, little attention was paid to its pharmacological properties due to the complicated and inefficient extract method. In recent years, with the development of extraction technology corilagin was much easier to obtain than before. Thus, people return to pay attention to its anti-tumor, hepatoprotective, and anti-inflammatory activities, particularly as an anti-tumor agent candidate. Our research team had focused on the distribution, preparation and anti-tumor activity of corilagin since 2005. We found corilagin showed good anti-tumor activity on hepatocellular carcinoma and ovarian cancer. What’s more, corilagin showed a low level of toxicity toward normal cells and tissues. Due to the extensive attention that corilagin has received, we present a systematic review of the pharmacological effects of corilagin. In this review, we summarized all the pharmacological effects of corilagin with a focus on the molecular mechanism of anti-tumor activity and show you how corilagin affected the signaling pathways of tumor cells as well as its physicochemical properties, distribution and preparation methods.

中文翻译：

---

Corilagin，一种有前途的草药制剂


Corilagin 是一种没食子单宁，是许多民族药理学植物的主要活性成分之一。它是与（雅克）威尔德隔离的。 (dividivi) 由施密特于 1951 年首次提出。在过去的几十年里，据报道柯里拉京表现出抗肿瘤、抗炎和保肝活性。然而，由于提取方法复杂且效率低下，其药理特性很少受到关注。近年来，随着提取技术的发展，科里拉金比以前更容易获得。因此，人们重新关注其抗肿瘤、保肝和抗炎活性，特别是作为抗肿瘤候选药物。我们的研究团队自2005年起就重点研究柯里拉金的分布、制备及其抗肿瘤活性。我们发现柯里拉京对肝细胞癌和卵巢癌表现出良好的抗肿瘤活性。此外，柯里拉京对正常细胞和组织的毒性较低。由于科里拉金受到广泛关注，我们对科里拉金的药理作用进行了系统评价。在这篇综述中，我们总结了柯里拉金的所有药理作用，重点关注抗肿瘤活性的分子机制，并向您展示了柯里拉京如何影响肿瘤细胞的信号通路，以及其理化性质、分布和制备方法。